In these times of high political uncertainty, it is particularly important to follow an investment approach that can help you to perform well across different macroeconomic and geopolitical scenarios.I specialize in constructing investment portfolios aimed at generating additional income through dividends. My focus lies on identifying companies with significant competitive advantages and strong financials that can provide you with an attractive Dividend Yield and Dividend Growth, thus enabling you to augmen ...

What happened According to an SEC filing dated Feb. 2, 2026, Artemis Investment Management LLP initiated a new stake in Commercial Metals Company (NYSE:CMC) by acquiring 1,501,906 shares during the fourth quarter. The estimated transaction value was $103.96 million, calculated using the quarter’s average share price. The quarter-end value of the position matched this figure, reflecting the combined impact of the share purchase and any price movement during the period. What else to know Artemis’s new Com ...

Key Takeaways AbbVie reports Q4 and full-year 2025 earnings Feb. 4, with sales expected above $16.3B and EPS near $2.66.ABBV's newer immunology drugs Skyrizi and Rinvoq are expected to fuel growth as Humira sales keep declining.AbbVie stock trades below industry P/E, driven by a growing pipeline and diversification across franchises.AbbVie (ABBV) is set to report fourth-quarter and full-year 2025 earnings on Feb. 4, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings i ...

Tech giants Alphabet Inc. and Amazon.com Inc. anchor a dense earnings week, with Alphabet Inc. reporting after close Wednesday and Amazon.com Inc. after close Thursday. Major pharmaceuticals including Eli Lilly and Company, AbbVie Inc., Novartis AG, and Novo Nordisk A/S report pre-market Wednesday. Significant activity in industrials and energy is noted on Tuesday, while insurance, semiconductors, and real estate sectors see multiple reports throughout the week, extending into Next Monday. Disclaimer: This ...

Group 1: AbbVie - AbbVie is recognized as a Dividend King, having increased its payouts for at least 50 consecutive years, indicating strong business stability [2] - The company has a diverse portfolio of medicines and a robust pipeline, which positions it well to maintain consistent revenue and earnings despite patent expirations [3] - AbbVie is expected to benefit from long-term trends such as the aging global population, which will increase demand for pharmaceutical products [6] Group 2: Mastercard - Mastercard has increased its dividend payouts by nearly 358% over the past decade, showcasing its strong business fundamentals [7] - The company processes credit and debit card transactions and is insulated from credit risk, allowing it to perform well even during economic downturns [8] - Mastercard has a significant addressable market, estimated at approximately $12.5 trillion, and is well-positioned to capitalize on the ongoing shift from cash to digital payments [10][11]

Core Viewpoint - AbbVie Inc. is considered one of the best healthcare stocks to buy for 2026, with Goldman Sachs reaffirming a Neutral rating and a price target of $223 ahead of its Q4 2025 earnings and 2026 guidance release [1] Financial Performance - Goldman Sachs projects AbbVie will achieve $67.1 billion in revenue for 2026, with $21.3 billion from Skyrizi and $10.4 billion from Rinvoq, alongside an EPS of $14.22, which aligns with consensus expectations [1] - A slight revenue beat is anticipated in Q4, driven by Skyrizi's performance exceeding expectations, while Rinvoq is expected to perform slightly below [2] Business Segments - The Aesthetics business is under continued pressure, while Neurology and Oncology are expected to show steady results [2] - AbbVie has a high P/E ratio of 168.95, reflecting strong growth expectations, supported by a dividend yield of 3.09% [2] Clinical Trials - AbbVie reported mixed results in the phase 3 Lymphoma trial for epcoritamab, showing improved progression-free survival but failing to meet the overall survival endpoint [3] - The adverse events observed were consistent with the known safety profile of the candidate drug [3] Strategic Response - AbbVie and its partner Genmab are investigating potential factors that may have negatively influenced the trial results, including the impact of the COVID-19 pandemic and the availability of new anti-lymphoma therapies [4] Company Overview - AbbVie is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for complex health issues, specializing in immunology, oncology, neuroscience, and eye care [5]

Core Viewpoint - AbbVie Inc. is recognized as one of the 12 best long-term stocks to buy, despite facing some challenges in clinical trials [1]. Group 1: Market Analysis - Citi has adjusted its price target for AbbVie to $230 from $235 while maintaining a Neutral rating, indicating a more supportive backdrop for the biopharma sector in 2026 due to manageable earnings expectations and reduced policy-related risks [2]. - The overall sentiment in the biopharma space suggests that earnings may exceed previous fears, contributing to a more favorable investment environment [2]. Group 2: Clinical Developments - AbbVie and Genmab's blood cancer drug, epcoritamab, did not demonstrate a statistically significant survival benefit in a late-stage study involving 483 patients with relapsed or refractory diffuse large B-cell lymphoma [3]. - Despite the lack of clear survival benefits, the study revealed positive outcomes, such as a higher number of patients achieving undetectable cancer levels, longer response durations, and improved time before requiring further treatment [4]. - Epcoritamab is already approved in several countries for other lymphoma indications, marketed as Epkinly in the U.S. and Japan, and as Tepkinly in the European Union [5].

Core Insights - The article discusses the author's background in analytics and accounting, highlighting over 10 years of experience in the investment sector, progressing from an analyst to a management role [1]. Group 1 - The author holds a master's degree in Analytics from Northwestern University and a bachelor's degree in Accounting [1]. - The author has a personal interest in dividend investing and aims to share insights with the Seeking Alpha community [1]. Group 2 - The author has disclosed a beneficial long position in several companies, including ABBV, ADP, HRL, JNJ, LOW, PEP, and SPGI, through various financial instruments [2]. - The article emphasizes that the author's opinions are personal and not influenced by compensation from any company mentioned [2].

AbbVie (NYSE: ABBV) is one of the largest pharmaceutical companies in the world. Though its portfolio spans many therapeutic areas, it is particularly well known for its work in immunology, a field in which it boasts some of the best-selling therapies. However, many smaller drugmakers are trying to break into this space. One of them, Abivax (NASDAQ: ABVX), has grabbed quite a few headlines of late thanks to a potentially transformative immunology medicine still in development. Should investors opt for the ...

Core Viewpoint - Analysts expect AbbVie (ABBV) to report quarterly earnings of $2.66 per share, reflecting a year-over-year increase of 23.2%, with revenues projected at $16.36 billion, up 8.3% from the previous year [1] Earnings Estimates - Changes in earnings estimates are crucial for predicting investor reactions, with empirical research showing a strong correlation between earnings estimate revisions and short-term stock performance [2] Revenue Projections - Analysts estimate 'Net Revenue- Imbruvica' at $714.90 million, indicating a year-over-year decline of 15.7% [4] - 'Net Revenue- Botox Therapeutic- Total' is expected to reach $995.91 million, reflecting a year-over-year increase of 14.1% [4] - 'Net Revenue- Venclexta' is projected at $725.34 million, suggesting a year-over-year increase of 10.7% [4] Neuroscience and Humira Revenue - 'Net Revenue- Neuroscience- Total' is estimated at $3.00 billion, indicating a year-over-year increase of 19.5% [5] - 'Net Revenue- Humira- US' is expected to be $574.85 million, reflecting a significant decline of 53.9% from the prior year [5] - 'Net Revenue- Humira- International' is projected at $374.40 million, indicating a year-over-year decrease of 14.1% [6] Oncology and New Products - 'Net Revenue- Oncology- Elahere- Total' is expected to reach $191.62 million, reflecting a year-over-year increase of 29.5% [6] - 'Net Revenue- Epkinly- International' is projected at $48.50 million, suggesting a substantial year-over-year increase of 120.5% [6] - 'Net Revenue- Qulipta- U.S.' is estimated at $271.58 million, indicating a year-over-year increase of 46% [7] - 'Net Revenue- Qulipta- International' stands at $39.74 million, reflecting a significant year-over-year increase of 165% [8] Stock Performance - AbbVie shares have decreased by 3.5% over the past month, contrasting with the Zacks S&P 500 composite's increase of 0.9%, and the stock is expected to closely follow the overall market with a Zacks Rank 3 (Hold) [8]